Categories: NewsPharmaceutical

Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

MORRISTOWN, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full-year 2022 financial results on Thursday, March 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.  

Participants can access the conference call live via webcast which will be available on the investor page of the company’s website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event’s start. A replay of the call will be available on Intercept’s website following the completion of the call.   
   
About Intercept   
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
  
Contact   
For more information about Intercept, please contact:   

Investor inquiries: investors@interceptpharma.com 

Media inquiries: media@interceptpharma.com 
  

 

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC – Issue of Equity

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…

2 hours ago

1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth

VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / 1933 Industries Inc. (the "Company"…

2 hours ago

Bupa Hong Kong has selected Cognizant to deliver an AI-driven BPaaS solution to transform health insurance claims

Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business…

5 hours ago

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

11 hours ago

CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech

BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…

11 hours ago

Therap Services Announces 2026 National Conference Schedule: Highlighting New Tools, Best Practices, and Over 250 Specialized Sessions

TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

11 hours ago